Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy

In 2018, a multi‐disciplinary workshop was held at the Massachusetts General Hospital to discuss challenges in defining, diagnosing, and treating immune‐related adverse events (irAE), including those that occur in patients administered PD‐1/L1 inhibitor combination therapy. In this commentary, the w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zubiri, Leyre, Allen, Ian M., Taylor, Martin S., Guidon, Amanda C., Chen, Steven T., Schoenfeld, Sara R., Neilan, Tomas G., Sise, Meghan E., Mooradian, Meghan J., Rubin, Krista M., Leaf, Rebecca Karp, Parikh, Aparna R., Faje, Alexander, Gainor, Justin F., Cohen, Justine V., Fintelmann, Florian J., Kohler, Minna J., Dougan, Michael, Reynolds, Kerry L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066708/
https://www.ncbi.nlm.nih.gov/pubmed/32162817
http://dx.doi.org/10.1634/theoncologist.2018-0883
Descripción
Sumario:In 2018, a multi‐disciplinary workshop was held at the Massachusetts General Hospital to discuss challenges in defining, diagnosing, and treating immune‐related adverse events (irAE), including those that occur in patients administered PD‐1/L1 inhibitor combination therapy. In this commentary, the workshop participants present a clinical case that illustrates the complexity of irAE diagnosis and management in a patient receiving PD‐1/L1 combination therapy, summarize the current state of PD‐1/L1 combination therapy, and discuss challenges and opportunities for the evaluation of irAEs as these combinations become more widely used to treat patients with cancer.

Ejemplares similares